Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc

New Microbiologica

Volumn 37, Issue 2, 2014, Pages 225-229

  Ermocida, Angel ^a   Mengoni, Fabi ^a   Sauzullo, Ilari ^a   Rossi, Raffaell ^a   Ajassa, Camill ^a   Lichtner, Miria ^a   Mastroianni, Claudio M ^a   Vullo, Vincenz ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Cell migration; Darunavir; HIV; Maraviroc

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; DARUNAVIR; MARAVIROC; SULFONAMIDE; TRIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CULTURE; CYTOLOGY; DRUG COMBINATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MONONUCLEAR CELL; NEUTROPHIL; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

ANTI-HIV AGENTS; APOPTOSIS; CELLS, CULTURED; CYCLOHEXANES; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUTROPHILS; SULFONAMIDES; TRIAZOLES;

EID: 84900398587     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Badley A. D. (2005). In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell. Death. Differ. 12 (Suppl. 1), 924-931.
2. Corbeau P., Reynes J. (2009). CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS. 23, 1931-1943.
3. Ghibelli L., Mengoni F., Lichtner M., Coppola S., De Nicola M., Bergamaschi A, Mastroianni C., Vullo V. (2003). Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. Biochem. Pharmacol. 66, 1505-1512.
4. Klatt N. R., Funderburg N. T., Brenchley J. M. (2013). Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 21, 6-13.
5. Klatt N. R., Chomont N., Douek D. C., Deeks S. G. (2013). Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol. Rev. 254, 326-342.
6. Latronico T., Liuzzi G. M., Riccio P., Lichtner M., Mengoni F., D'Agostino C., Vullo V., Mastroianni C. M. (2007). Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS. 21, 677-684.
7. Lichtner M., Mengoni F., Mastroianni C. M., Sauzullo I., Rossi R., De Nicola M., Vullo V., Ghibelli L. (2006). HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. Apoptosis. 11, 781-787.
8. Mastroianni C. M., Mengoni F., Lichtner M., D'Agostino C., d'Ettorre G., Forcina G., Marzi M., Russo G., Massetti A. P., Vullo V. (2000). Ex vivo and in vitro effect of Human Immunodeficiency Virus protease inhibitors on neutrophil apoptosis. J. Infect. Dis. 182, 1536-1569.
9. Mastroianni C. M., Liuzzi G. M. (2007). Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol. Med. 13, 449-459.
10. Phenix B. N., Cooper C., Owen C., Badley A. D. (2002). Modulation of apoptosis by HIV protease inhibitors. Apoptosis. 7, 295-312.
11. Rossi R, Lichtner M, Sauzullo I, Mengoni F, Marocco R, Massetti AP, Mastroianni CM, Vullo V. (2010). Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J. Acquir. Immune Defic. Syndr. 54, e13-14.
12. Rossi R., Lichtner M., De Rosa A., Sauzullo I., Mengoni F., Massetti A. P., Mastroiann i C. M., Vullo V. (2011). In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin. Exp. Immunol. 166, 184-190.